Fig. 1
From: The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells
Expression and targeting of CRM1 in non-Hodgkin lymphoma cells. a Immunoblot showing the expression of CRM1 protein in DLBCL, TCL, and MCL cell lines, and normal B and T-cells. b Proliferation assay on representative TCL, MCL, and DLBCL cell lines treated with various concentrations of KPT-330 for 48 h. Data shown in percentage are normalized with non-drug treated controls. c Cell cycle analysis of representative cell lines (a) Karpas-299 (TCL) and (b) Jeko-1 (MCL) after 24 h incubation with various concentrations of KPT-330. d Apoptosis assay data on representative cell lines of TCL, MCL, and DLBCL after treatment with various concentrations of KPT-330 for 48 h. e Immunofluorescence staining of IkB-alpha in Jeko-1 (MCL) cells upon treatment with 2.5 µM of KPT-330 for 24 h. DLBCL diffuse large B-cell lymphoma, MCL Mantle cell lymphoma, TCL T-cell lymphoma, CRM1 chromosome region maintenance 1
